Melior: Multiplexed reprofiling

Emerging Company Profile

Melior Discovery Inc. has developed a multiplexed in vivo reprofiling system that it believes is more efficient than one-off in vivo models and more predictive than cell-based in vitro approaches. Last week, the company announced a fourth fee-for-service deal with a pharma partner, this time AstraZeneca plc. Revenue from Melior’s service deals will be used to build out its own pipeline of reprofiled molecules...